Monivent (MONI) Q3 2024 earnings summary

Executive summary

• Focus on securing a global distribution agreement with Dräger and advancing regulatory approvals for broader market expansion.

• Bridge loan obtained to address immediate capital needs, with plans for a rights issue of approximately 13 MSEK.

• Clinical study published showing significant improvement in manual ventilation quality with Neo100.

Financial highlights

• Net sales for Q3 2024 were 227 KSEK, down from 925 KSEK in Q3 2023; for Jan–Sep 2024, net sales were 1,451 KSEK, down from 2,533 KSEK year-over-year.

• Operating costs for Q3 2024 were 2,498 KSEK, down from 3,962 KSEK; Jan–Sep 2024 costs were 9,702 KSEK, down from 13,500 KSEK.

• EBIT for Q3 2024 was -2,271 KSEK (vs. -2,994 KSEK); Jan–Sep 2024 EBIT was -8,238 KSEK (vs. -10,817 KSEK).

• Cash and cash equivalents at period end were 72 KSEK, down from 3,823 KSEK a year earlier.

• Earnings per share for Jan–Sep 2024 were -0.40 SEK (vs. -1.01 SEK year-over-year).

Outlook and guidance

• Intends to submit FDA 510(k) application in the coming months following completion of a user study at Stanford.

• Strategic shift to concentrate sales through a global partner to accelerate market exposure.